A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologi… (NCT07255898) | Clinical Trial Compass
Not Yet RecruitingPhase 1
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
China33 participantsStarted 2025-12
Plain-language summary
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-M24D1 in patients with relapsed or refractory multiple myeloma and other hematologic malignancies.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Voluntarily sign the informed consent form and comply with the protocol requirements;
✓. Gender is not restricted;
✓. Age: ≥18 years and ≤75 years (Phase Ia); ≥18 years (Phase Ib);
✓. Expected survival time ≥3 months;
✓. Histologically and/or cytologically confirmed multiple myeloma or other hematologic malignancies that have failed standard treatment or for which no standard treatment currently exists;
✓. Must have measurable indicators as defined by the protocol;
✓. Physical condition score ECOG 0 or 1;
✓. Toxicity from previous antitumor treatments has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
Exclusion criteria
✕. Subjects with central nervous system involvement, etc.;
✕. Use of chemotherapy, biologics, immunotherapy, etc., within 4 weeks prior to the first dose or within 5 half-lives;